Search results
Lumos Pharma plans phase 3 trial for growth hormone drug By Investing.com
Investing.com· 5 hours agoLumos Pharma Inc. (NASDAQ:LUMO), a biopharmaceutical company focused on rare diseases, announced...
KORU Medical enters Phase III trial for rare disease therapy By Investing.com
Investing.com· 5 hours agoKORU Medical Systems, Inc. (NASDAQ: KRMD), a company specializing in large volume subcutaneous...
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine...
WJTV Jackson· 14 hours agoAs part of the collaboration, PhaseV conducted an independent analysis of NeuroSense's PARADIGM Phase 2b study using a causal ML...
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials By Investing.com
Investing.com· 5 hours agoThe company highlighted the clearance of their Investigational New Drug (IND) application by the FDA...
Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
Clinical Trials Arena via Yahoo Finance· 15 hours agoUS-based biotechnology company Kodiak Sciences has dosed the first subjects with diabetic...
...to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of...
WJTV Jackson· 6 days ago(Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular ...
Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology...
FOX 23 News Albany· 10 hours agoUpdated data from the Phase I trial of RVU120 in patients with relapsed/refractory acute myeloid...
Innovent’s mazdutide superior to Trulicity in Phase III T2D trial
Clinical Trials Arena via Yahoo Finance· 5 days agoThe US will maintain a majority of the global market share at 48.5%. GlobalData is the parent...
...Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose...
Morningstar· 6 hours agoALACHUA, Fla. and CHICAGO, May 14, 2024 /PRNewswire/ -- Nanopharmaceutics, Inc. (OTC:TGRP), a clinical-stage pharmaceutical development company, announced the initiation of ...
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
WRBL Columbus· 1 day ago"We are pleased that the feedback from the U.S. Food and Drug Administration (FDA) supports the advancement of larsucosterol into a single pivotal Phase 3 clinical ...